Stock CORT CORCEPT THERAPEUTICS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Market Closed - Nasdaq
Other stock markets
 03:59:52 2024-05-30 pm EDT 		5-day change 1st Jan Change
31.16 USD -1.20% Intraday chart for Corcept Therapeutics Incorporated +11.93% -4.06%
May. 28 Sector Update: Health Care Stocks Retreat Tuesday Afternoon MT
May. 28 Corcept Therapeutics Says Phase 3 Hypercortisolism Trial Meets Primary Endpoint; Shares Advance MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients with Hypercortisolism
AQ
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
GL
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
AQ
Corcept: Q1 Earnings Snapshot
AQ
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
GL
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
AQ
Corcept Completes Enrollment in Phase 4 CATALYST Trial
GL
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
GL
Corcept Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing's syndrome
AQ
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
GL
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
GL
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
GL
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
GL
Corcept: Q4 Earnings Snapshot
AQ
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
GL
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
GL
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
GL
When Does A Drug Label Induce Infringement Under 35 U.S.C. § 271(e)(2) Of A Patent Not Claiming An Indication Or Method Of Use?
AQ
Corcept Appoints Roberto Vieira as President, Oncology
GL
Corcept Appoints Roberto Vieira as President, Oncology
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CORT Stock
  4. News Corcept Therapeutics Incorporated
  5. Press Releases